Novo Nordisk today announced new data for semaglutide medicines to be presented at the American College of Cardiology 74th Annual Scientific Session and Expo (ACC.25). These new cardiometabolic data, spanning multiple, inter-related chronic diseases, will provide new information about semaglutide medicines to reduce cardiovascular (CV) risk and improve functional capacity in treating certain patient populations.
Data spans various cardiometabolic conditions, including type 2 diabetes (T2D), obesity, peripheral arterial disease, and chronic kidney disease.
SOUL, a phase 3 trial, explored reduction of major adverse cardiovascular events (MACE) in patients with type 2 diabetes and atherosclerotic cardiovascular and/or chronic kidney disease.
SCORE study evaluated use of semaglutide 2.4 mg and MACE risk reduction in real-world settings.
STRIDE phase 3 data offers new insights on functional capacity with the use of injectable semaglutide 1 mg for people with type 2 diabetes and peripheral artery disease.
Primary phase 3 data from the SOUL trial explored reduction of major adverse cardiovascular events (MACE) in patients with type 2 diabetes and atherosclerotic cardiovascular and/or chronic kidney disease.1 The SCORE study evaluated use of semaglutide 2.4 mg and MACE risk reduction in real-world settings.2
Examining improvements in functional capacity in PAD
In STRIDE, investigators examined the primary endpoint of change in maximum walking distance on a constant load treadmill test among adult patients with symptomatic peripheral artery disease (PAD) and type 2 diabetes.3
These new data underscore the company’s focus on driving change to defeat some of the most serious chronic diseases affecting the world today and improving patient care. Collectively, type 2 diabetes, obesity, peripheral arterial disease and chronic kidney disease affect millions of Americans and can contribute to significant long-term health risks and complications, including cardiovascular disease (CVD)
Entdecke mehr von LabNews
Melde dich für ein Abonnement an, um die neuesten Beiträge per E-Mail zu erhalten.
